{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:53:36Z","timestamp":1771581216509,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,8]],"date-time":"2017-01-08T00:00:00Z","timestamp":1483833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.cmi.2016.12.032","type":"journal-article","created":{"date-parts":[[2017,1,7]],"date-time":"2017-01-07T23:49:32Z","timestamp":1483832972000},"page":"391-395","source":"Crossref","is-referenced-by-count":20,"title":["Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori \u2013related chronic gastritis: a prospective randomized study in China"],"prefix":"10.1016","volume":"23","author":[{"given":"L.","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl.\u00a01","key":"10.1016\/j.cmi.2016.12.032_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hel.12165","article-title":"Epidemiology of Helicobacter pylori infection","volume":"19","author":"Eusebi","year":"2014","journal-title":"Helicobacter"},{"key":"10.1016\/j.cmi.2016.12.032_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/gutjnl-2015-309197","article-title":"A\u00a0large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication","volume":"65","author":"Pan","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2016.12.032_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-1-62703-005-2_2","article-title":"Helicobacter pylori: an overview","volume":"921","author":"Noto","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.cmi.2016.12.032_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/gut.41.2.169","article-title":"Relation between Helicobacter pylori infection and gastrointestinal symptoms and syndromes","volume":"41","author":"Rosenstock","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2016.12.032_bib5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1365-2036.2003.01695.x","article-title":"Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia","volume":"18","author":"Malfertheiner","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cmi.2016.12.032_bib6","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1056\/NEJM199812243392601","article-title":"Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia","volume":"339","author":"McColl","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.12.032_bib7","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2016.12.032_bib8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1523-5378.1996.tb00027.x","article-title":"Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study","volume":"1","author":"Lind","year":"1996","journal-title":"Helicobacter"},{"key":"10.1016\/j.cmi.2016.12.032_bib9","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1572-0241.2007.01393.x","article-title":"American College of Gastroenterology guideline on the management of Helicobacter pylori infection","volume":"102","author":"Chey","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cmi.2016.12.032_bib10","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infection\u2014the Maastricht IV\/Florence Consensus Report","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2016.12.032_bib11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/gut.2009.198309","article-title":"Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design","volume":"59","author":"Liou","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2016.12.032_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(11)60825-8","article-title":"14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial","volume":"378","author":"Greenberg","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2016.12.032_bib13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.7326\/0003-4819-146-8-200704170-00006","article-title":"Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial","volume":"146","author":"Vaira","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2016.12.032_bib14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"Review article: the global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"Thung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cmi.2016.12.032_bib15","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00000478-199610000-00001","article-title":"Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston, 1994","volume":"20","author":"Dixon","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cmi.2016.12.032_bib16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1523-5378.2012.00971.x","article-title":"Helicobacter pylori eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a randomized, open-label, phase IV trial","volume":"17","author":"Liang","year":"2012","journal-title":"Helicobacter"},{"key":"10.1016\/j.cmi.2016.12.032_bib17","first-page":"1134","article-title":"Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China","volume":"25","author":"Lu","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2016.12.032_bib18","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1053\/j.gastro.2005.11.059","article-title":"Functional gastroduodenal disorders","volume":"130","author":"Tack","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2016.12.032_bib19","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.3748\/wjg.v16.i40.5118","article-title":"Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai","volume":"16","author":"Sun","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cmi.2016.12.032_bib20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1523-5378.2010.00788.x","article-title":"The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China","volume":"15","author":"Gao","year":"2010","journal-title":"Helicobacter"},{"key":"10.1016\/j.cmi.2016.12.032_bib21","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1136\/gutjnl-2015-309900","article-title":"Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy","volume":"64","author":"Zhang","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2016.12.032_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1473-3099(06)70627-2","article-title":"Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications","volume":"6","author":"Gerrits","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2016.12.032_bib23","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/gutjnl-2015-311019","article-title":"Role of bismuth in improving Helicobacter pylori eradication with triple therapy","volume":"65","author":"Dore","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2016.12.032_bib24","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gutjnl-2013-306120","article-title":"Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial","volume":"63","author":"Liu","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2016.12.032_bib25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/hel.12296","article-title":"Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third-line treatment of Helicobacter pylori infection: two pilot studies","volume":"21","author":"Ciccaglione","year":"2016","journal-title":"Helicobacter"},{"key":"10.1016\/j.cmi.2016.12.032_bib26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.clinre.2015.12.012","article-title":"Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains","volume":"40","author":"Muller","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.cmi.2016.12.032_bib27","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1046\/j.1365-2036.2002.01311.x","article-title":"Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis","volume":"16","author":"Ito","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cmi.2016.12.032_bib28","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1440-1746.1996.tb00312.x","article-title":"Long-term follow-up of gastric histology after Helicobacter pylori eradication","volume":"11","author":"Forbes","year":"1996","journal-title":"J\u00a0Gasteroenterol Hepatol"},{"key":"10.1016\/j.cmi.2016.12.032_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/gast.2000.8550","article-title":"Atrophy and intestinal metaplasia one year after cure of H.\u00a0pylori infection: a prospective, randomized study","volume":"119","author":"Sung","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2016.12.032_bib30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrgastro.2013.9","article-title":"Helicobacter pylori infection in functional dyspepsia","volume":"10","author":"Suzuki","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X17300022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X17300022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T06:52:25Z","timestamp":1536130345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X17300022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1198743X17300022"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2016.12.032","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}